用于早期卵巢癌检测的基于血清的生物标志物的开发所面临的挑战。
Challenges related to developing serum-based biomarkers for early ovarian cancer detection.
机构信息
Clinical Genetics Branch,Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, USA.
出版信息
Cancer Prev Res (Phila). 2011 Mar;4(3):303-6. doi: 10.1158/1940-6207.CAPR-11-0053.
Abstract
In this issue of the journal, Cramer and colleagues and Zhu and colleagues report carefully designed phase 3 assessments of candidate ovarian cancer screening biomarkers. The main conclusion is that CA-125 remains the "best of a bad lot"; the new candidates have fallen short of expectations. We review factors impeding the development of an effective ovarian cancer screening strategy, highlight the requirements related to validating proposed screening biomarkers, and emphasize the risks from premature clinical applications of unvalidated tests, all underscoring the need for new research strategies.
摘要
在本期杂志中，Cramer 及其同事以及 Zhu 及其同事报告了精心设计的候选卵巢癌筛查生物标志物的 3 期评估。主要结论是 CA-125 仍然是“差中之差”；新的候选者未能达到预期。我们回顾了阻碍有效卵巢癌筛查策略发展的因素，强调了与验证拟议筛查生物标志物相关的要求，并强调了未经验证的测试过早临床应用的风险，所有这些都强调了需要新的研究策略。
相似文献
1
Challenges related to developing serum-based biomarkers for early ovarian cancer detection.用于早期卵巢癌检测的基于血清的生物标志物的开发所面临的挑战。
Cancer Prev Res (Phila). 2011 Mar;4(3):303-6. doi: 10.1158/1940-6207.CAPR-11-0053.
2
The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples.发现用于卵巢癌早期检测的新型生物标志物的必要条件：精心挑选的临床前样本。
Cancer Prev Res (Phila). 2011 Mar;4(3):299-302. doi: 10.1158/1940-6207.CAPR-11-0048.
3
Personalizing CA125 levels for ovarian cancer screening.针对卵巢癌筛查的 CA125 水平个体化。
Cancer Prev Res (Phila). 2011 Sep;4(9):1356-9. doi: 10.1158/1940-6207.CAPR-11-0378.
4
Protein biomarkers of ovarian cancer: the forest and the trees.卵巢癌的蛋白质生物标志物：只见树木，不见森林。
Future Oncol. 2012 Jan;8(1):55-71. doi: 10.2217/fon.11.135.
5
Role of microRNAs as Clinical Cancer Biomarkers for Ovarian Cancer: A Short Overview.miRNAs 作为卵巢癌临床癌症生物标志物的作用：简要概述。
Cells. 2020 Jan 9;9(1):169. doi: 10.3390/cells9010169.
6
Ovarian Cancer Biomarkers: Moving Forward in Early Detection.卵巢癌生物标志物：在早期检测方面的进展。
Adv Exp Med Biol. 2020;1219:355-363. doi: 10.1007/978-3-030-34025-4_18.
7
Prognostic biomarkers in ovarian cancer.卵巢癌的预后生物标志物。
Cancer Biomark. 2010;8(4-5):231-51. doi: 10.3233/CBM-2011-0212.
8
Early Detection of Ovarian Cancer.卵巢癌的早期检测
Hematol Oncol Clin North Am. 2018 Dec;32(6):903-914. doi: 10.1016/j.hoc.2018.07.003. Epub 2018 Sep 28.
9
The quest for ovarian cancer screening biomarkers: are we on the right road?寻找卵巢癌筛查生物标志物：我们是否走在正确的道路上？
Int J Gynecol Cancer. 2012 May;22 Suppl 1:S35-40. doi: 10.1097/IGC.0b013e318251ccaa.
10
Estimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCS.评估卵巢癌CA-125临床前可检测阶段、体内肿瘤倍增时间及早期检测窗口：英国卵巢癌筛查协作组的探索性分析
EBioMedicine. 2025 Feb;112:105554. doi: 10.1016/j.ebiom.2024.105554. Epub 2025 Jan 13.
引用本文的文献
1
Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy.子宫平滑肌肉瘤的综合综述：发病机制、诊断、预后和靶向治疗。
Cells. 2024 Jun 26;13(13):1106. doi: 10.3390/cells13131106.
2
Serum biomarker-based early detection of pancreatic ductal adenocarcinomas with ensemble learning.基于血清生物标志物的胰腺癌早期检测的集成学习方法
Commun Med (Lond). 2023 Jan 20;3(1):10. doi: 10.1038/s43856-023-00237-5.
3
MUC16 Is Overexpressed in Idiopathic Pulmonary Fibrosis and Induces Fibrotic Responses Mediated by Transforming Growth Factor-β1 Canonical Pathway.MUC16 在特发性肺纤维化中过度表达，并通过转化生长因子-β1 经典途径诱导纤维化反应。
Int J Mol Sci. 2021 Jun 17;22(12):6502. doi: 10.3390/ijms22126502.
4
Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers.了解卵巢癌的蛋白质组学概况：发现疾病生物标志物之路。
Proteomes. 2021 May 25;9(2):25. doi: 10.3390/proteomes9020025.
5
The function of LncRNAs and their role in the prediction, diagnosis, and prognosis of lung cancer.长链非编码 RNA 的功能及其在肺癌预测、诊断和预后中的作用。
Clin Transl Med. 2021 Apr;11(4):e367. doi: 10.1002/ctm2.367.
6
Circulating long non-coding RNA (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies.循环长链非编码RNA（生长停滞特异性转录本5）作为一种用于通过液体活检检测恶性间皮瘤的补充标志物。
Biomark Res. 2020 May 13;8:15. doi: 10.1186/s40364-020-00194-4. eCollection 2020.
7
Deep Metabolomics of a High-Grade Serous Ovarian Cancer Triple-Knockout Mouse Model.高级别浆液性卵巢癌三敲除小鼠模型的深度代谢组学研究。
J Proteome Res. 2019 Aug 2;18(8):3184-3194. doi: 10.1021/acs.jproteome.9b00263. Epub 2019 Jul 10.
8
Healthy human serum N-glycan profiling reveals the influence of ethnic variation on the identified cancer-relevant glycan biomarkers.健康人血清 N-糖链分析揭示了种族差异对鉴定出的与癌症相关糖生物标志物的影响。
PLoS One. 2018 Dec 28;13(12):e0209515. doi: 10.1371/journal.pone.0209515. eCollection 2018.
9
Current Standards and Recent Advances in Biomarkers of Major Endocrine Tumors.主要内分泌肿瘤生物标志物的当前标准与最新进展
Front Pharmacol. 2018 Sep 10;9:963. doi: 10.3389/fphar.2018.00963. eCollection 2018.
10
Another Round of "Clue" to Uncover the Mystery of Complex Traits.新一轮“线索”揭示复杂性状之谜。
Genes (Basel). 2018 Jan 25;9(2):61. doi: 10.3390/genes9020061.
本文引用的文献
1
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.用于早期检测的生物标志物评估框架：卵巢癌生物标志物组合的验证。
Cancer Prev Res (Phila). 2011 Mar;4(3):375-83. doi: 10.1158/1940-6207.CAPR-10-0193.
2
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.在前列腺癌、肺癌、结直肠癌和卵巢癌筛查试验标本中卵巢癌生物标志物的性能。
Cancer Prev Res (Phila). 2011 Mar;4(3):365-74. doi: 10.1158/1940-6207.CAPR-10-0195.
3
Status of tumor markers in epithelial ovarian cancer has there been any progress? A review.上皮性卵巢癌肿瘤标志物的研究现状：是否有进展？一篇综述。
Gynecol Oncol. 2011 Jan;120(1):152-7. doi: 10.1016/j.ygyno.2010.09.002. Epub 2010 Oct 14.
4
Cancer biomarkers: can we turn recent failures into success?癌症生物标志物：我们能否将最近的失败转化为成功？
J Natl Cancer Inst. 2010 Oct 6;102(19):1462-7. doi: 10.1093/jnci/djq306. Epub 2010 Aug 12.
5
Conflicting views on the molecular structure of the cancer antigen CA125/MUC16.对癌症抗原 CA125/MUC16 的分子结构存在不同看法。
Dis Markers. 2010;28(6):385-94. doi: 10.3233/DMA-2010-0719.
6
Cancer statistics, 2010.癌症统计数据，2010 年。
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7.
7
Biomarkers for ovarian cancer detection and therapy.卵巢癌检测和治疗的生物标志物。
Cancer Biol Ther. 2010 May 1;9(9):668-77. doi: 10.4161/cbt.9.9.11610. Epub 2010 May 24.
8
Ovarian cancer: the duplicity of CA125 measurement.卵巢癌：CA125 检测的双重性。
Nat Rev Clin Oncol. 2010 Jun;7(6):335-9. doi: 10.1038/nrclinonc.2010.44. Epub 2010 Apr 6.
9
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.上皮性卵巢癌的起源和发病机制：一种提出的统一理论。
Am J Surg Pathol. 2010 Mar;34(3):433-43. doi: 10.1097/PAS.0b013e3181cf3d79.
10
Clinical practice. Screening for ovarian cancer.临床实践。卵巢癌筛查。
N Engl J Med. 2009 Jul 9;361(2):170-7. doi: 10.1056/NEJMcp0901926.
Zotero 插件